Literature DB >> 3415896

Absorption and bioavailability of nebulized morphine.

J Chrubasik1, H Wüst, G Friedrich, E Geller.   

Abstract

During anaesthesia seven patients received a bolus of morphine 10 mg injected into the nebulization reservoir placed between the tracheal tube and the anaesthetic circle (IH). Five days after operation the same seven patients received morphine 10 mg i.m. On both occasions, venous blood samples were taken before and every 15 min after administration over 4.5 h for measurement of free morphine immunoreactivity by radioimmunoassay. There was marked individual variation in the serum morphine concentrations produced following each route of administration. The maximum serum morphine concentration following inhaled morphine was approx. six times lower than that after morphine i.m. and the time of occurrence differed significantly (P less than 0.001). The individual relative bioavailabilities of inhaled morphine varied from 9% to 35%, with a mean of 17%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415896     DOI: 10.1093/bja/61.2.228

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  10 in total

1.  [Pharmacokinetics of intranasal Fentanyl.].

Authors:  H W Striebel; J Krämer; I Luhmann; I Rohierse-Hohler; A Rieger
Journal:  Schmerz       Date:  1993-06       Impact factor: 1.107

2.  Nebulised drugs in palliative care.

Authors:  S Ahmedzai; C Davis
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 3.  Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care.

Authors: 
Journal:  BMJ       Date:  1996-03-30

Review 4.  Dyspnea: assessment and treatment.

Authors:  M Farncombe
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

5.  Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery.

Authors:  L E Mather; A Woodhouse; M E Ward; S J Farr; R A Rubsamen; L G Eltherington
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

6.  Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease.

Authors:  M Farncombe; S Chater
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

7.  Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease.

Authors:  A R Masood; J W Reed; S H Thomas
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

8.  Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study.

Authors:  Majid Shohrati; Mostafa Ghanei; Asghar Amini Harandi; Soniya Foroghi; Ali Amini Harandi
Journal:  Pulm Med       Date:  2012-03-19

9.  Morphine and alternative opioids in cancer pain: the EAPC recommendations.

Authors:  G W Hanks; F Conno; N Cherny; M Hanna; E Kalso; H J McQuay; S Mercadante; J Meynadier; P Poulain; C Ripamonti; L Radbruch; J R Casas; J Sawe; R G Twycross; V Ventafridda
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

Review 10.  Inhaled opioids for cancer pain relief: A narrative review.

Authors:  Magdalena Osowicka; Piotr Janowiak; Agnieszka Gorzewska; Monika Lichodziejewska-Niemierko
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.